Pyxis Oncology (PYXS) Fundamental Analysis: Revenue, Earnings & Valuation

4.20 / 10

Netural

Comprehensive analysis: average fundamentals (4.2/10). Positive dimensions: Interest coverage ratio (EBIT / Interest expense) (%) and Revenue-MV, but headwinds are noted in Asset-MV and Fixed assets turnover ratio. Resulting position: constrained.

Analysis Checks(7/10)

Revenue-MV

Value-0.31

Score3/3

Weight59.79%

1M Return7.95%

Total operating revenue (YoY growth rate %)

Value-14.17

Score2/3

Weight2.41%

1M Return0.41%

Inventory turnover ratio

Value98.02

Score2/3

Weight-6.27%

1M Return-1.19%

Profit-MV

Value0.62

Score2/3

Weight26.09%

1M Return4.10%

PB-ROE

Value-0.28

Score1/3

Weight10.86%

1M Return1.95%

Fixed assets turnover ratio

Value0.67

Score1/3

Weight-9.07%

1M Return-1.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value39.04

Score2/3

Weight-5.81%

1M Return-1.07%

Operating revenue (YoY growth rate %)

Value-14.17

Score2/3

Weight4.01%

1M Return0.68%

Cost of sales ratio (%)

Value17.23

Score2/3

Weight-7.29%

1M Return-1.40%

Asset-MV

Value-0.72

Score1/3

Weight25.28%

1M Return3.90%

Is PYXS undervalued or overvalued?

PYXS scores 4.20/10 on fundamentals and holds a Fair valuation at present. Backed by its -91.43% ROE, -574.55% net margin, -1.17 P/E ratio, 1.74 P/B ratio, and 3.03% earnings growth, these metrics solidify its Netural investment rating.